scholarly journals Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report

2021 ◽  
Vol 9 (10) ◽  
pp. 2394-2399
Author(s):  
Zhi-Yun Niu ◽  
Li Sun ◽  
Shu-Peng Wen ◽  
Zheng-Rong Song ◽  
Lina Xing ◽  
...  
Keyword(s):  
T Cells ◽  
Cell Death ◽  
Case Report ◽  
Programmed Cell Death ◽  
Hodgkin Lymphoma ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Non Hodgkin Lymphoma ◽  
Cell Death Protein

Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy

Cytotherapy ◽  
2020 ◽  
Vol 22 (12) ◽  
pp. 734-743 ◽  
Author(s):  
Ang Zhang ◽  
Yao Sun ◽  
Shenyu Wang ◽  
Jie Du ◽  
Xiangyun Gao ◽  
...  
Keyword(s):  
T Cells ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Cell Death Protein

Effective gmp-compliant point of care manufacturing of anticd19 chimeric antigen receptor t cells for non hodgkin lymphoma patients using the clinimacs prodigy®

Cytotherapy ◽  
2020 ◽  
Vol 22 (5) ◽  
pp. S133
Author(s):  
S. Kleinsorge-Block ◽  
J. Payne-Schiavone ◽  
K. Zamborsky ◽  
T.L. Turney ◽  
J. Reese ◽  
...  
Keyword(s):  
T Cells ◽  
Hodgkin Lymphoma ◽  
Chimeric Antigen Receptor ◽  
Point Of Care ◽  
Antigen Receptor ◽  
Non Hodgkin Lymphoma

Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL)

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S118-S119 ◽  
Author(s):  
M.M. Davis ◽  
A. Fesnak ◽  
R.M. Leskowitz ◽  
J.S. McKee ◽  
Y. Ohayon ◽  
...  
Keyword(s):  
T Cells ◽  
Hodgkin Lymphoma ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Car T Cells ◽  
Non Hodgkin Lymphoma ◽  
Car T
Sign in / Sign up

Export Citation Format

Share Document